Nautilus Biotechnology, Inc. (NASDAQ:NAUT - Get Free Report)'s stock price traded down 7.5% during trading on Thursday . The stock traded as low as $0.75 and last traded at $0.75. 209,762 shares changed hands during trading, an increase of 30% from the average session volume of 160,889 shares. The stock had previously closed at $0.81.
Nautilus Biotechnology Price Performance
The company has a market cap of $98.59 million, a PE ratio of -1.45 and a beta of 1.42. The firm's 50 day moving average is $0.76 and its 200 day moving average is $1.13.
Nautilus Biotechnology (NASDAQ:NAUT - Get Free Report) last released its quarterly earnings results on Tuesday, April 29th. The company reported ($0.13) EPS for the quarter, topping analysts' consensus estimates of ($0.14) by $0.01. As a group, analysts anticipate that Nautilus Biotechnology, Inc. will post -0.57 EPS for the current year.
Institutional Investors Weigh In On Nautilus Biotechnology
A number of hedge funds have recently made changes to their positions in NAUT. Presidio Capital Management LLC increased its stake in shares of Nautilus Biotechnology by 246.6% in the second quarter. Presidio Capital Management LLC now owns 34,664 shares of the company's stock worth $25,000 after buying an additional 24,664 shares during the period. Acadian Asset Management LLC raised its holdings in Nautilus Biotechnology by 468.3% during the 1st quarter. Acadian Asset Management LLC now owns 61,735 shares of the company's stock valued at $51,000 after buying an additional 50,871 shares during the last quarter. Jacobs Levy Equity Management Inc. bought a new stake in Nautilus Biotechnology during the 1st quarter valued at $194,000. Nuveen LLC bought a new stake in Nautilus Biotechnology during the 1st quarter valued at $167,000. Finally, Fayez Sarofim & Co bought a new stake in Nautilus Biotechnology during the 1st quarter valued at $39,000. 50.71% of the stock is currently owned by institutional investors.
About Nautilus Biotechnology
(
Get Free Report)
Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.
Featured Stories
Before you consider Nautilus Biotechnology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nautilus Biotechnology wasn't on the list.
While Nautilus Biotechnology currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
